Alzheimer's disease (AD) is a neurodegenerative disorder primarily caused by the toxic effects of amyloid-β (Aβ), making understanding therapies critical.
4-Phenylbutyric acid (4-PBA) shows promise in reducing Aβ toxicity, potentially functioning as a chemical chaperone or inhibiting histone deacetylases (HDACs).
In a study using the nematode Caenorhabditis elegans, 4-PBA improved movement and diminished Aβ aggregation, with findings suggesting that its effectiveness relies on activating a heat shock response via HSF-1 while inhibiting HDA-1.